ArticleJournal of gastrointestinal oncology2025
Comprehensive bioinformatic analysis reveals sorafenib response-related prognostic signature in hepatocellular carcinoma.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations.Journal of gastrointestinal oncology · 2026Article
- Clinical outcomes and prognostic factors of systemic therapy combined with interventional treatment in hepatocellular carcinoma: a multicenter retrospective case series.Translational cancer research · 2026Article
- Development and internal validation of a prognostic model for hepatocellular carcinoma after liver resection based on the albumin-bilirubin score and triglyceride-glucose index.Translational cancer research · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sorafenib is the first-line treatment agent for advanced hepatocellular carcinoma (HCC), but it is effective in very few patients. Thus, this study was intended to identify gene signatures associated with sorafenib response in HCC and construct a prognostic risk model based on these gene signatures. Methods: The gene expression level data of HCC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. First, we evaluated the HCC sensitivity to sorafenib of the samples and investigated the correlation between HCC sensitivity to sorafenib and clinical prognosis. By Weighted Gene Co-Expression Network Analysis (WGCNA) algorithm, the sorafenib resistance associated genes were obtained. Combined with the sorafenib resistance related data set, genes significantly associated sorafenib responses were screened. Then prognostic signature genes were screened to construct a risk prognosis model. The correlation of risk grouping with immune cells was explored. Results: A total of 399 significantly genes associated with sorafenib response were obtained, which were involved in metabolic and complement pathways. Finally, 5 signature genes ( Conclusions: Our study established a sorafenib response-related prognostic risk prediction model in HCC based on five signature genes (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.